Galapagos selected for BEL 20 Index
March 07 2016 - 1:34AM
Galapagos NV (Euronext & NASDAQ: GLPG) announces that
Euronext has selected Galapagos NV for inclusion in the BEL 20®
Index on Euronext Brussels, effective 21 March 2016.
The BEL 20 represents the 20 largest companies
traded on Euronext Brussels, subject to meeting Euronext Index
Family criteria and review. For a complete overview of
criteria and index rules, please see The Index Family Rulebook, at
www.euronext.com.
"We are proud that in our 11th year as a listed
company on Euronext, and our 17th year since we were incorporated
in 1999, we are now included in the BEL 20, the prestigious index
of largest public companies in Belgium. It shows the growth
of Galapagos from a biotech start-up to an integrated discovery and
development company that is bringing innovative new medicines to
patients," says Onno van de Stolpe, CEO and Founder.
About Galapagos Galapagos (Euronext & NASDAQ: GLPG)
is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action. Our pipeline comprises three Phase 2, three
Phase 1, five pre-clinical, and 20 discovery studies in cystic
fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We have discovered and developed filgotinib: in
collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 440 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information at
www.glpg.com.
CONTACT
Investors: Media:
Elizabeth
Goodwin Evelyn
Fox VP IR & Corporate
Communications Director
Communications +1 781 460
1784
+31 6 53 591 999
ir@glpg.com
communications@glpg.com
Forward-Looking Statements This release may contain
forward-looking statements, including statements. Galapagos
cautions the reader that forward-looking statements are not
guarantees of future performance. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition and
liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results,
performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. A list and description of
these risks, uncertainties and other risks can be found in
Galapagos' Securities and Exchange Commission (SEC) filings and
reports, including in Galapagos' prospectus filed with the SEC on
14 May 2015 and subsequent filings and reports filed by Galapagos
with the SEC. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based or
that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless
specifically required by law or regulation.
Galapagos selected for BEL 20 Index
http://hugin.info/133350/R/1992188/733164.pdf
HUG#1992188
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024